Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 7/20 | 0.58 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | BCL6 | P41182 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14230821 | 0.83 | NUDT1 (0.58) | NUDT1GRM4BCL6NOS3NOS1 | |
| SCHEMBL16011451 | 0.80 | NUDT1 (0.42) | NUDT1BCL6 | |
| SCHEMBL12586215 | 0.77 | NUDT1 (0.35) | NUDT1NOS3NOS1NOS2 | |
| SCHEMBL20150284 | 0.77 | JAK1 (0.46) | NUDT1GRM4PTPN1BCL6DHFR | |
| SCHEMBL14994344 | 0.77 | BCL6 (0.56) | NUDT1GRM4PTPN1BCL6 | |
| SCHEMBL2744648 | 0.77 | BCL6 (0.56) | NUDT1PTPN1BCL6 | |
| SCHEMBL20150368 | 0.77 | NUDT1 (0.40) | NUDT1BCL6 | |
| SCHEMBL12568005 | 0.76 | AURKA (0.44) | NUDT1 | |
| SCHEMBL2745948 | 0.75 | DHFR (0.43) | NUDT1DHFR | |
| SCHEMBL6457831 | 0.74 | XDH (0.42) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016145383-A1 | MTH1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-9040543-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140363443-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846908-B2 | Tricyclic carbamate JAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8729087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-7560466-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7122542-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | NUDT1 1609/4885GRM4 4381/4885PTPN1 140/4885 |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | NUDT1 38/4885GRM4 1093/4885PTPN1 3907/4885 |
| US-20140363443-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | JAK3, JAK2, JAK1 | NUDT1 1239/4885GRM4 2951/4885PTPN1 480/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | NUDT1 379/4885GRM4 4528/4885PTPN1 3370/4885 |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | JAK1, JAK3, JAK2 | NUDT1 4062/4885GRM4 3461/4885PTPN1 60/4885 |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | NUDT1 38/4885GRM4 1093/4885PTPN1 3907/4885 |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | NUDT1 4420/4885GRM4 3418/4885PTPN1 124/4885 |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NUDT1 2025/4885GRM4 4300/4885PTPN1 176/4885 |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | SSB, TYMS, TPMT | NUDT1 38/4885GRM4 1093/4885PTPN1 3907/4885 |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | NUDT1 3822/4885GRM4 4117/4885PTPN1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.